These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 26584873)
1. Substrate-based inhibitors exhibiting excellent protective and therapeutic effects against Botulinum Neurotoxin A intoxication. Guo J; Wang J; Gao S; Ji B; Waichi Chan E; Chen S Sci Rep; 2015 Nov; 5():16981. PubMed ID: 26584873 [TBL] [Abstract][Full Text] [Related]
2. Unique substrate recognition by botulinum neurotoxins serotypes A and E. Chen S; Barbieri JT J Biol Chem; 2006 Apr; 281(16):10906-11. PubMed ID: 16478727 [TBL] [Abstract][Full Text] [Related]
3. Differential endopeptidase activity of different forms of type A botulinum neurotoxin: A unique relationship between the size of the substrate and activity of the enzyme. Ambrin G; Kumar R; Singh BR Toxicon; 2018 Mar; 144():34-41. PubMed ID: 29309744 [TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs. Shi DY; Lu JS; Mao YY; Liu FJ; Wang R; Du P; Yu S; Yu YZ; Yang ZX Appl Microbiol Biotechnol; 2023 May; 107(10):3205-3216. PubMed ID: 37058230 [TBL] [Abstract][Full Text] [Related]
5. Interactions of a potent cyclic peptide inhibitor with the light chain of botulinum neurotoxin A: Insights from X-ray crystallography. Kumaran D; Adler M; Levit M; Krebs M; Sweeney R; Swaminathan S Bioorg Med Chem; 2015 Nov; 23(22):7264-73. PubMed ID: 26522088 [TBL] [Abstract][Full Text] [Related]
6. Multiple pocket recognition of SNAP25 by botulinum neurotoxin serotype E. Chen S; Barbieri JT J Biol Chem; 2007 Aug; 282(35):25540-7. PubMed ID: 17609207 [TBL] [Abstract][Full Text] [Related]
7. Mechanism of substrate recognition by botulinum neurotoxin serotype A. Chen S; Kim JP; Barbieri JT J Biol Chem; 2007 Mar; 282(13):9621-9627. PubMed ID: 17244603 [TBL] [Abstract][Full Text] [Related]
8. Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin. Patel KB; Cai S; Adler M; Singh BK; Parmar VS; Singh BR Appl Environ Microbiol; 2018 Dec; 84(24):. PubMed ID: 30389764 [TBL] [Abstract][Full Text] [Related]
9. Strategies to design inhibitors of Clostridium botulinum neurotoxins. Cai S; Singh BR Infect Disord Drug Targets; 2007 Mar; 7(1):47-57. PubMed ID: 17346211 [TBL] [Abstract][Full Text] [Related]
10. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. Pier CL; Chen C; Tepp WH; Lin G; Janda KD; Barbieri JT; Pellett S; Johnson EA FEBS Lett; 2011 Jan; 585(1):199-206. PubMed ID: 21126520 [TBL] [Abstract][Full Text] [Related]
11. The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site. Mizanur RM; Frasca V; Swaminathan S; Bavari S; Webb R; Smith LA; Ahmed SA J Biol Chem; 2013 Aug; 288(33):24223-33. PubMed ID: 23779108 [TBL] [Abstract][Full Text] [Related]
12. Characterization of the functional activity of botulinum neurotoxin subtype B6. Kohda T; Nakamura K; Hosomi K; Torii Y; Kozaki S; Mukamoto M Microbiol Immunol; 2017 Nov; 61(11):482-489. PubMed ID: 28898517 [TBL] [Abstract][Full Text] [Related]
13. In vitro potency determination of botulinum neurotoxin serotype A based on its receptor-binding and proteolytic characteristics. Behrensdorf-Nicol HA; Wild E; Bonifas U; Klimek J; Hanschmann KM; Krämer B; Kegel B Toxicol In Vitro; 2018 Dec; 53():80-88. PubMed ID: 30016653 [TBL] [Abstract][Full Text] [Related]
14. Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A. Ho M; Goh CH; Brothers MC; Wang S; Young RL; Ou Y; Lui JN; Kalafatis M; Lan X; Wolf AE; Rienstra CM; Wilson BA Protein Sci; 2012 Mar; 21(3):318-26. PubMed ID: 22170566 [TBL] [Abstract][Full Text] [Related]
15. Small Molecule Receptor Binding Inhibitors with In Vivo Efficacy against Botulinum Neurotoxin Serotypes A and E. Ben David A; Barnea A; Diamant E; Dor E; Schwartz A; Torgeman A; Zichel R Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445283 [TBL] [Abstract][Full Text] [Related]
16. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Tsai YC; Maditz R; Kuo CL; Fishman PS; Shoemaker CB; Oyler GA; Weissman AM Proc Natl Acad Sci U S A; 2010 Sep; 107(38):16554-9. PubMed ID: 20823219 [TBL] [Abstract][Full Text] [Related]
17. Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors. Li B; Cardinale SC; Butler MM; Pai R; Nuss JE; Peet NP; Bavari S; Bowlin TL Bioorg Med Chem; 2011 Dec; 19(24):7338-48. PubMed ID: 22082667 [TBL] [Abstract][Full Text] [Related]
18. Botulinum neurotoxin serotype A inhibitors: small-molecule mercaptoacetamide analogs. Moe ST; Thompson AB; Smith GM; Fredenburg RA; Stein RL; Jacobson AR Bioorg Med Chem; 2009 Apr; 17(8):3072-9. PubMed ID: 19329331 [TBL] [Abstract][Full Text] [Related]
19. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species. Atassi MZ; Dolimbek BZ; Hayakari M; Middlebrook JL; Whitney B; Oshima M J Protein Chem; 1996 Oct; 15(7):691-700. PubMed ID: 8968960 [TBL] [Abstract][Full Text] [Related]